biostudies-literatureUnknown48(12)Graham TETandem Diabetes Care<h4>Objective</h4>To assess the effect of automated insulin delivery (AID) on glycemic and insulin outcomes in adults with insulin-treated type 2 diabetes using a glucagon-like peptide-1 receptor agonist (GLP-1 RA).<h4>Research design and methods</h4>In a randomized trial comparing Control-IQ+ AID versus continuation of prestudy insulin delivery method plus continuous glucose monitoring (CGM group), 143 (45%) of the 319 participants were using a GLP-1 RA at baseline, which was continued during the trial.<h4>Results</h4>Among GLP-1 RA users, mean HbA1c decreased by 0.8% from a baseline of 8.0 ± 1.2% with AID, which represented a mean improvement of -0.5% (95% CI -0.8 to -0.3, P < 0.001) compared with the CGM group. Time-in-range 70-180 mg/dL and other CGM metrics reflective of hyperglycemiaDiabetes care2154-2159https://www.ebi.ac.uk/biostudies/studies/S-EPMC12635876biostudies-literatureAdditive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes.PMC12635876Tsoukas MTamarez DStrayer HWilliams JEstrada KSpanakis EKBrouillard EDiFrancesco KKollar LHerrmann SStewart AHunter HSasson-Katchalski RSpaic TAverkiou XCaswell BDalton-Bakes CHatipoglu BRezac SBeck RWLiljenquist DRBrown SASwinton SBellini NMurphy CPasqua MKollman CBlevins TAia CKemp GTajrishi FZWolpert HHolod RRickels MRWhite KAhmann AKudva YCArroyo LGAtakov-Castillo AKanapka LJordan LFTerry AChristensen RMalone JLee IShao BMorrell BHoward QVander-Heide JHoward MPhan MLum JWDenallo EPiquette NVancer LAlabi DPasquel FJTsoukas MAKhakpour DHaidar AKruger D2IQP Study Group*Agostini LCasaubon LMitchell TBecerra MRizvi SDriscoll MOliveri MCurtis SBzdick SKaur RJPayra STardio VMellenthin MLevy CJOladejo OCoyne KKravarusic JKamimoto JJJones JKHassan SMorales ATribout MMeeks TLivingood DChurchill JLuker RSingh LCostello RLevister CMTribout JAleppo GLayton PMukhashen SPandit KBranigan DHeyerman TSteenkamp DWReyes-Rodriguez CDavis GMEllis EBulger JPeleckis AJLe VHendricks LPinsker JEComen KAhn DCampos TSullivan AEmory EWeinstock RSGabrielson DLewis CCarmelo KCO'Malley GWheatcroft ACorker NLesniak ASultan RSchmid CSpanbauer CFronczyk EFields CFulkerson DLapier HTessman BDhillon JLitvicov PLiu SGraham TEPenn SEspinosa VScott WRaskin PUsman SHirsch IBRaghinaru DAssir CMandava PToole ERogers JCardenas-Villamil GPerez JStone SBaran JDesjardins DKurek CPhillips KIpek AMercado KMarks SDean AWolf VSmith JDoNguyen THolmes VHairston BOgyaadu SFuller MOduah VBourne PDennis BMoore AAfreen SBroyles FJanicek RfalseAdditive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes.<h4>Objective</h4>To assess the effect of automated insulin delivery (AID) on glycemic and insulin outcomes in adults with insulin-treated type 2 diabetes using a glucagon-like peptide-1 receptor agonist (GLP-1 RA).<h4>Research design and methods</h4>In a randomized trial comparing Control-IQ+ AID versus continuation of prestudy insulin delivery method plus continuous glucose monitoring (CGM group), 143 (45%) of the 319 participants were using a GLP-1 RA at baseline, which was continued during the trial.<h4>Results</h4>Among GLP-1 RA users, mean HbA1c decreased by 0.8% from a baseline of 8.0 ± 1.2% with AID, which represented a mean improvement of -0.5% (95% CI -0.8 to -0.3, P < 0.001) compared with the CGM group. Time-in-range 70-180 mg/dL and other CGM metrics reflective of hyperglycemia2025-01-01T00:00:00Z2025 Dec2026-05-20T03:16:29.151Z2026-05-20T03:12:27.025ZS-EPMC126358764126482810.2337/dc25-1753